【ChiCTR2000039133】Randomized controlled trial of Enhancing Contact Model on reducing stigma of mental illness in family caregivers of persons with schizophrenia in rural China
ChiCTR2000039133
结束
/
/
/
2020-10-18
/
/
精神分裂症
Randomized controlled trial of Enhancing Contact Model on reducing stigma of mental illness in family caregivers of persons with schizophrenia in rural China
Randomized controlled trial of Enhancing Contact Model on reducing stigma of mental illness in family caregivers of persons with schizophrenia in rural China
The study tests the short (post- intervention) and long-term (9-month follow-up) effectiveness of a newly developed Enhancing Contact Model (ECM) Intervention for reducing self-stigma in family caregivers of persons with schizophrenia, and examines whether ECM is more effective on reducing self-stigma than Psychoeducational Family Intervention (PFI).
随机平行对照
其它
Computer generated numbers for randomization
Not stated
Research Grants Council, University Grants Committee, General Research Fund
/
97;88;84
/
2018-09-01
2021-02-28
/
The inclusion criteria for family caregivers: 1. Being the father or mother of a person with schizophrenia identified in 2015; 2. Aged 38- 75 years; 3. Living together with and caring for the patient; 4. Not participants in our prior PFI studies; 5. Be able to provide written informed consent. The inclusion criteria for person with schizophrenia: 1. Be identified in the 2015 survey; 2. Aged >=18 years; 3. Not participants in our prior PFI studies.；
请登录查看The exclusion criteria for the family caregivers: 1. likely to engage in a risk behavior (e.g., suicide or violence) imminently; 2. Be identified by a trained health professional as unsuitable to join the study (e.g., with mental illness).；
请登录查看香港大學社會科學學院
/
香港大學社會科學學院的其他临床试验
香港大學社會科學學院的其他临床试验
- “厨厨有爱”：新来港人士社区融合计划
- Randomized controlled trial of Enhancing Contact Model on reducing stigma of mental illness in family caregivers of persons with schizophrenia in rural China
- World Health Organization Caregiver Skills Training (WHO-CST) Programme for Hong Kong Chinese families of young children with developmental delays or Autism Spectrum Disorders– Phase Three: evaluation of the pilot implementation
最新临床资讯
-
一项5年临床安全随访研究启示：#脐带间充质干细胞（#hUC-MSCs）
SCLnow圣释2026-11-11
-
SYNCHRONIZE-CVOT试验达到主要终点，索弗度肽（survodutide）成为全球首个证实心血管安全性的胰高血糖素/GLP-1双受体激动剂
勃林格殷格翰中国2026-11-11
-
医药观澜2026-11-11
-
宜明昂科2026-11-11
-
医学科学院精准医学研究所2026-11-11
-
多肽圈2026-11-11
-
多肽圈2026-11-11
-
求是网2026-11-11
-
干细胞之父2026-11-11
-
和田维药2026-11-11
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-11-12
-
2026-11-12
-
2026-11-12
-
摩熵咨询 20 3
-
摩熵咨询 33 62
-
摩熵咨询 20 3
-
颁布机构：国家卫生健康委办公厅、 2026-11-10
-
颁布机构：国家卫健委（原国家卫计委） 2026-11-10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-11-11
-
2026-11-11
-
2026-11-11
-
摩熵咨询 35 92
-
摩熵咨询 28 74
-
摩熵咨询 34 49
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-07
-
颁布机构：国家市场监督管理总局 2026-11-04